Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial
- Wednesday, May 10, 2023, 7:00
- Finance
- Add a comment
Total 1Q 2023 revenue on FYARRO® sales of $5.9 million PRECISION 1 tumor agnostic trial enrolling equally in TSC1 and TSC2 arms with more than 15 discreet tumor types represented Interim analysis on 40 patients with appropriate follow-up in PRECISION 1 trial expected by end of 2023…
About the Author
adminasapcorp has written 41608 stories on this site.